Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Sponsor: Novartis Pharmaceuticals
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Novartis Pharmaceuticals
Other Leukemia, Myeloid, Chronic trials with similar outcome
A PHASE2 clinical study on Leukemia, Myeloid, Chronic, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Completed → Terminated · Phase: PHASE2_PHASE3 → PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .